RNXT — RenovoRx, Inc.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 10
- Website: https://renovorx.com
Latest SEC filings for RNXT
- RW — 2026-10-16
- 8-K — 2026-08-20
- 8-K/A — 2026-08-13
- 10-Q — 2026-08-13
- 8-K — 2026-08-12
- 8-K — 2026-08-04
- 8-K — 2026-07-02
- 8-K — 2026-06-30
- S-8 — 2026-06-30
- 10-K/A — 2026-05-15
Latest RNXT news
- — RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial (globenewswire.com)
- — RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer (globenewswire.com)
Educational tool only — not investment advice.